Canonical text (the exact bytes fingerprinted)

TRUVACE RECORD VERSION
record: TRV-2026-2002
version: 1
kind: certified
reason: Certified into the record
timestamp: 2026-10-20T10:42:18.083470Z
status: published
lens: trace
sector: health
headline: Artificial intelligence in personalized internal dosimetry for radiopharmaceutical therapy: a narrative mini-review
dek: Personalized internal radiation dosimetry supports individualized radiopharmaceutical therapy but remains difficult to implement because workflows require repeated quantitative imaging, segmentation, registration, kinetic modeling, and absorbed-dose calculation. This mini-review summarizes current evidence on artificial intelligence across the personalized dosimetry workflow and considers clinical readiness. A narrative PubMed search was completed in early 2026 and covered peer-reviewed studies published from 20…
gain_title: Deep learning cut Y-90 SPECT reconstruction error and sped up image registration, easing workflow burdens that make individualized radiopharmaceutical dosimetry hard to implement.
problem_title: AI-based clinical decision support for dosimetry rests mainly on retrospective, single-center evidence and still needs prospective, multicenter validation before routine clinical use.
trace_subject: AI in personalized internal dosimetry for radiopharmaceutical therapy
gain_reading: Deep learning cut Y-90 SPECT reconstruction error and sped up image registration, easing workflow burdens that make individualized radiopharmaceutical dosimetry hard to implement.
gain_evidence: Deep learning reduced yttrium-90 single-photon emission computed tomography reconstruction error from 149.5% ± 31.2% to 9.2% ± 1.7% | Learning-based registration reduced computation time from about 50 s to under 6 s.
problem_reading: AI-based clinical decision support for dosimetry rests mainly on retrospective, single-center evidence and still needs prospective, multicenter validation before routine clinical use.
problem_evidence: evidence for artificial intelligence-based clinical decision support remains mainly retrospective and single-center | decision-support applications still require prospective, multicenter validation
quick_read: A narrative mini-review surveyed peer-reviewed studies from 2015 to early 2026 on machine learning and deep learning applied to personalized internal dosimetry. It covered image reconstruction, segmentation, registration, time-activity curve estimation, absorbed-dose calculation and decision support. Reported results included large drops in reconstruction error and faster registration.

Dosimetry-guided radiopharmaceutical therapy depends on a multi-step workflow that is hard to run in routine practice, so tools that shorten or simplify steps could widen access to individualized dosing. The review finds readiness uneven: reconstruction and segmentation look closer to clinical use, while decision-support tools lack prospective, multicenter evidence. Because this is a narrative review rather than a systematic one, the evidence base may be incompletely captured.
limitation: The evidence for AI-based clinical decision support is mainly retrospective and single-center, and decision-support tools still need prospective, multicenter validation.
tag: Dual reading
key_points: Deep learning lowered Y-90 SPECT reconstruction error from 149.5% ± 31.2% to 9.2% ± 1.7% in the cited work. | Lesion dose-rate error was 8.6% ± 5.7% in virtual-patient testing. | Learning-based registration cut computation time from about 50 s to under 6 s. | Automated segmentation shows improving reproducibility, and machine learning has been explored for predicting organ effective half-life. | Reconstruction and segmentation appear nearer clinical readiness than decision-support applications.
rundown: The review identifies the barriers to personalized dosimetry as repeated quantitative imaging, segmentation, registration, kinetic modeling and absorbed-dose calculation. It examines AI at each of these steps, prioritizing studies that reported quantitative performance or validation results.

The headline accuracy figures come from specific tasks. The Y-90 SPECT reconstruction improvement is a reported reduction in error, and the 8.6% lesion dose-rate error was measured in virtual-patient testing rather than in a clinical cohort.

Single-time-point approaches may simplify imaging requirements, and recent machine learning work has explored predicting organ effective half-life. Automated segmentation reproducibility is described as improving.

On clinical readiness, the authors conclude that reconstruction and segmentation applications are closer to use, whereas decision-support tools remain supported mostly by retrospective, single-center studies.
sources:
- peer_reviewed | Nuclear Medicine Communications | https://doi.org/10.1097/mnm.0000000000002253 | 2026-10-20
prev: 0000000000000000000000000000000000000000000000000000000000000000

sha256

ff104b4ee9303c95c900e561e9c9650ea85a7cb6442c4b92c4782d7a07c3b58d

previous

0000000000000000000000000000000000000000000000000000000000000000